{"id":"NCT00909779","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","officialTitle":"A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2009-05-28","resultsPosted":"2013-11-11","lastUpdate":"2013-11-11"},"enrollment":841,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Arformoterol","otherNames":["Brovana"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arformoterol 15 mcg twice daily","type":"EXPERIMENTAL"},{"label":"Placebo twice daily","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation will consist of a total of 6 visits over approximately 1 year.","primaryOutcome":{"measure":"Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).","timeFrame":"0-12 months","effectByArm":[{"arm":"Experimental: Arformoterol 15 Mcg Twice Daily","deltaMin":155,"sd":91.2},{"arm":"Placebo","deltaMin":171.7,"sd":98.7}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":16,"exclusionCount":17},"locations":{"siteCount":73,"countries":["United States"]},"refs":{"pmids":["28011247","25451347"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":95,"n":421},"commonTop":["Chronic obstructive pulmonary disease","Bronchitis","Nasopharyngitis","Headache","Dyspnoea"]}}